FFRI Security, Inc. (TYO:3692)

Intra-Cellular Therapies Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2020
Net Income	880	540	247	156	331
Depreciation & Amortization	43	41	53	52	59
Loss (Gain) From Sale of Assets	-	-	-	-	10
Loss (Gain) on Equity Investments	-43	-34	-38	-51	-1
Other Operating Activities	-141	-73	-7	-82	-104
Change in Accounts Receivable	-302	-356	-64	39	-31
Change in Accounts Payable	23	50	31	-52	-3
Change in Other Net Operating Assets	181	222	80	-78	-68
Operating Cash Flow	641	390	302	-16	193
Operating Cash Flow Growth	64.36%	29.14%	-	-	82.08%
Capital Expenditures	-24	-19	-11	-19	-7
Cash Acquisitions	-	-	-	-128	-
Sale (Purchase) of Intangibles	-22	-1	-15	-13	-57
Investment in Securities	-430	-	-	4	-
Other Investing Activities	-1	-	-	-1	-1
Investing Cash Flow	-477	-20	-26	-157	-65
Long-Term Debt Repaid	-	-	-	-11	-
Net Debt Issued (Repaid)	-	-	-	-11	-
Repurchase of Common Stock	-	-	-161	-260	-
Dividends Paid	-78	-	-	-	-
Other Financing Activities	-1	-50	-	-4	-
Financing Cash Flow	-79	-50	-161	-275	-
Miscellaneous Cash Flow Adjustments	-1	-1	-1	-1	-2
Net Cash Flow	84	319	114	-449	126
Free Cash Flow	617	371	291	-35	186
Free Cash Flow Growth	66.31%	27.49%	-	-	84.16%
Free Cash Flow Margin	20.30%	15.17%	14.91%	-1.97%	11.61%
Free Cash Flow Per Share	78.01	46.90	36.67	-4.33	22.71
Cash Income Tax Paid	140	74	26	83	101
Levered Free Cash Flow	466.63	285.63	252.88	-	95.75
Unlevered Free Cash Flow	466.63	285.63	252.88	-	95.75
Change in Net Working Capital	41	46	-99	-	113

Source: S&P Global Market Intelligence. Standard template. Financial Sources.